Abstract |
Cefepime, a wide-spectrum β- lactam antibiotic, has been in use for the treatment of serious bacterial infections for almost 25 years. Since its clinical development, there has been a dramatic shift in its dosing, with 2 g every 8 hours being preferred for serious infections to optimize pharmacokinetic/pharmacodynamic considerations. The advent of ESBLs has become a threat to its ongoing use, although future coadministration with β-lactamase inhibitors (BLIs) under development is an area of intense study. There are currently four new cefepime/BLI combinations in clinical development. Cefepime/zidebactam is generally active against MBL-producing Enterobacterales and Pseudomonas aeruginosa, in vitro and in animal studies, and cefepime/ taniborbactam has activity against KPC and OXA-48 producers. Cefepime/ enmetazobactam and cefepime/ tazobactam are potential carbapenem-sparing agents with activity against ESBLs. Cefepime/ enmetazobactam has completed Phase III and cefepime/ taniborbactam is in Phase III clinical studies, where they are being tested against carbapenems or piperacillin/tazobactam for the treatment of complicated urinary tract infections. While these combinations are promising, their role in the treatment of MDR Gram-negative infections can only be determined with further clinical studies.
|
Authors | Burcu Isler, Patrick Harris, Adam G Stewart, David L Paterson |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 76
Issue 3
Pg. 550-560
(02 11 2021)
ISSN: 1460-2091 [Electronic] England |
PMID | 33332545
(Publication Type: Journal Article)
|
Copyright | © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: [email protected]. |
Chemical References |
- Anti-Bacterial Agents
- Azabicyclo Compounds
- Borinic Acids
- Carboxylic Acids
- Cephalosporins
- Triazoles
- beta-Lactamase Inhibitors
- Cefepime
- enmetazobactam
- taniborbactam
- beta-Lactamases
|
Topics |
- Animals
- Anti-Bacterial Agents
(pharmacology, therapeutic use)
- Azabicyclo Compounds
- Borinic Acids
- Carboxylic Acids
- Cefepime
- Cephalosporins
(pharmacology)
- Microbial Sensitivity Tests
- Pseudomonas aeruginosa
- Triazoles
- beta-Lactamase Inhibitors
(pharmacology)
- beta-Lactamases
|